Improve people's lives

That is our purpose and the principle that has guided us since our foundation. We care for the health of people and we do it with passion and commitment

DISCOVER WHO WE ARE

Patients
Our Commitment

Patients

Our Commitment

Who we are

Learn how we've been delivering on our mission for patients for 90 years.

Stay in the loop with our latest news and developments

31/07/2025

ESTEVE ACQUIRES REGIS TECHNOLOGIES, EXPANDING U.S. PRESENCE AND CAPABILITIES

This acquisition enables ESTEVE to expand its contract development and manufacturing services for small-molecule active pharmaceutical ingredients from pre-clinical to commercial manufacturing in the US.

30/06/2025

ESTEVE TO ACQUIRE MEDICINE TO TREAT MEDULLARY THYROID CANCER

Caprelsa® (vandetanib) is a medicine that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer.

This is a new step forward in ESTEVE's international growth journey focused on highly specialized treatments for high unmet medical and patient needs.

10/07/2024

ESTEVE ACQUIRES HRA PHARMA RARE DISEASES

This expands ESTEVE's portfolio of medications for rare and severe diseases with three products to treat Cushing's syndrome and adrenocortical carcinoma; and drives its international growth.

16/05/2024

ESTEVE CONSOLIDATES ITS DOUBLE-DIGIT GROWTH AND REACHES €710 MILLION IN NET REVENUE

The company advances in its vision to be a leading international specialty pharmaceutical company, growing in Europe and expanding the portfolio

ESTEVE's medicines reached 8 million people worldwide over the past year

The company achieved zero emissions in Scope 2¹ reducing its carbon footprint by 5.3% compared to 2022